Press release
Neurotrophic Keratitis Emerging Pipeline and Marketed Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies | MimeTech, Dompé Farmaceutici, Oyster Point Pharma, Claris Biother
"Neurotrophic Keratitis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Neurotrophic Keratitis Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Neurotrophic Keratitis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Neurotrophic Keratitis Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurotrophic Keratitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neurotrophic Keratitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Neurotrophic Keratitis Therapeutics Domain:
https://www.delveinsight.com/report-store/neurotrophic-keratitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Neurotrophic Keratitis Therapeutics Analysis
Treatment of NK is mainly targeted toward the apparent specific symptoms in the respective patients. Topical eye medications are advised to stop immediately. Oxervate is the first medication that is approved by the US FDA for the treatment of NK patients. For patients who have worsening NK, a surgical approach is adopted for the treatment. During the treatment process, amniotic membrane placement may be considered for patients with corneal ulcerations that do not heal over time or with the severely affected cornea.
To further improve the Neurotrophic Keratitis treatment scenario, globally, several major pharma and biotech giants are actively working in the Neurotrophic Keratitis therapeutics market.
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/neurotrophic-keratitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Leading Companies in the Neurotrophic Keratitis Therapeutics Market Include:
• MimeTech
• Dompé Farmaceutici
• Oyster Point Pharma
• Claris Biotherapeutics
• ReGenTree
• Recordati Rare Diseases
And Many Others
Neurotrophic Keratitis Emerging and Marketed Drugs Covered in the Report Include:
• OXERVATE (Cenegermin-bkbj/rhNGF): Dompé Farmaceutici
• OC-01(varenicline/Chantix): Oyster Point Pharma
• REC 0559 (MT-8/Udonitrectag/ REC 0/0559): Recordati Rare Diseases/MimeTech
• CSB-001: Claris Biotherapeutics
• RGN-259 (Tβ4): ReGenTree
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/neurotrophic-keratitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Neurotrophic Keratitis Current Treatment Patterns
4. Neurotrophic Keratitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Neurotrophic Keratitis Late-Stage Products (Phase-III)
7. Neurotrophic Keratitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neurotrophic Keratitis Discontinued Products
13. Neurotrophic Keratitis Product Profiles
14. Neurotrophic Keratitis Key Companies
15. Neurotrophic Keratitis Key Products
16. Dormant and Discontinued Products
17. Neurotrophic Keratitis Unmet Needs
18. Neurotrophic Keratitis Future Perspectives
19. Neurotrophic Keratitis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/neurotrophic-keratitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurotrophic Keratitis Emerging Pipeline and Marketed Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies | MimeTech, Dompé Farmaceutici, Oyster Point Pharma, Claris Biother here
News-ID: 2967193 • Views: …
More Releases from DelveInsight Business Research LLP
Dry Eye Disease Treatment Market Outlook Report 2032 | Alcon Inc., AbbVie Inc., …
DelveInsight's Dry Eye Disease Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Dry Eye Disease Treatment Companies market shares, challenges, Dry Eye Disease Treatment Market Drivers, barriers, trends, and key market Dry Eye Disease Treatment companies in the market.
To read more about the latest highlights related to the Dry Eye Disease Treatment Market, get a snapshot of the key highlights entailed in the Market…
Digital Biopsy Market Size Report 2032 | DermaSensor, Inc., SciBase, VITA IMAGIN …
DelveInsight's Digital Biopsy Market Insights Report 2032 provides the current and forecast market analysis, individual leading Digital Biopsy Companies market shares, challenges, Digital Biopsy Market Drivers, barriers, trends, and key market Digital Biopsy companies in the market.
To read more about the latest highlights related to the Digital Biopsy Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/digital-biopsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Digital Biopsy Market…
Sinuscope Market Forecast Report 2032 | Olympus Corporation, Boston Scientific C …
DelveInsight's Sinuscope Market Insights Report 2032 provides the current and forecast market analysis, individual leading Sinuscope Companies market shares, challenges, Sinuscope Market Drivers, barriers, trends, and key market Sinuscope companies in the market.
To read more about the latest highlights related to the Sinuscope Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/sinuscope-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Sinuscope Market Report
• The Sinuscope Market is estimated to…
Skull Clamps Market Forecast Report 2032 | Integra LifeSciences Corporation, PRO …
DelveInsight's Skull Clamps Market Insights Report 2032 provides the current and forecast market analysis, individual leading Skull Clamps Companies market shares, challenges, Skull Clamps Market Drivers, barriers, trends, and key market Skull Clamps companies in the market.
To read more about the latest highlights related to the Skull Clamps Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/skull-clamp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Skull Clamps Market…
More Releases for Neurotrophic
Top Market Shifts Transforming the Neurotrophic Keratitis Treatment Market Lands …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Neurotrophic Keratitis Treatment Market Through 2025?
The valuation of the neurotrophic keratitis treatment sphere has experienced rapid expansion lately, projected to escalate from a figure of $1.08 billion in 2024 to $1.47 billion by 2025, reflecting a substantial compound annual growth rate…
Neurotrophic Keratitis Patient Pool Analysis Market Forecast to Grow at 8.2% CAG …
Introduction
Neurotrophic keratitis (NK) is a rare, degenerative corneal disease caused by impaired corneal innervation, leading to reduced or absent corneal sensitivity. This results in poor wound healing, epithelial breakdown, and in severe cases, corneal ulceration, scarring, and vision loss. Although classified as a rare disease, NK has a significant clinical impact due to its association with conditions such as herpes simplex virus (HSV) keratitis, herpes zoster ophthalmicus, diabetes, ocular surgeries,…
Neurotrophic Keratitis Treatment Market Landscape 2025: Forecast Data and Growth …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Neurotrophic Keratitis Treatment Market Through 2025?
The market size for treatment of neurotrophic keratitis has experienced robust growth in the last few years. The market, which was valued at $5.1 billion in 2024, is expected to reach $5.51 billion in 2025, reflecting…
Key Neurotrophic Keratitis Treatment Market Trend for 2025-2034: Innovative Drug …
What Is the Future Outlook for the Neurotrophic Keratitis Treatment Market's Size and Growth Rate?
The neurotrophic keratitis treatment market has experienced robust growth in recent years. It is forecasted to grow from $5.1 billion in 2024 to $5.51 billion in 2025, at a CAGR of 8.1%. Historical growth has been influenced by increased diagnoses, a rising number of injuries and surgical procedures, ongoing research and development efforts, and improvements in…
Advances in Neurotrophic Keratitis Treatment: Breakthroughs and Innovations
Neurotrophic keratitis is a rare and neurodegenerative disease that affects the cornea of an eye. This disease leads to reduction or loss of cornea sensitivity. It further leads to ulcer formation and ultimately corneal perforation.
Increase in special designation from the regulatory authorities is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure and upsurge in the demand for novel therapies and treatment…
Neurotrophic Keratitis Market Growth Set to Surge Significantly during 2019 - 20 …
Neurotrophic Keratitis Market: Introduction
Transparency Market Research has published a new report titled, "Global Neurotrophic Keratitis Market". According to the report, the global neurotrophic keratitis market was valued at US$ 91.6 Mn in 2018 and is projected to expand at a CAGR of ~17% from 2019 to 2027. Rise in reported cases of keratitis, increase in research & developmental activities, surge in awareness, and rise in co-morbidities & risk factors boost…
